MIRA Pharmaceuticals, Inc. Announces Engagement of Fractional Chief Financial Officer via Consulting Agreement
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has announced a significant development that could impact its operational and financial direction. On June 2, 2026, the company entered into a Consulting Agreement with LMAM Consulting Group, LLC to provide senior financial leadership in the role of a Fractional Chief Financial Officer (CFO).
Key Points from the Report
- Consultant Engagement: MIRA Pharmaceuticals has engaged LMAM Consulting Group, LLC to deliver fractional CFO services on an independent contractor basis, not as a company employee. This move is designed to bolster the company’s financial discipline, reporting accuracy, and capital markets readiness.
- Scope of Services: The consultant will provide oversight of financial reporting, SEC compliance, audit readiness, internal controls, capital-raising support, financial modeling, and board-level financial reporting. The services are specifically tailored to support MIRA’s regulatory, capital-markets, and strategic growth objectives.
-
Notable Service Deliverables:
- Preparation, review, and coordination of SEC filings (including Forms 10-K, 10-Q, and 8-K).
- Coordination of annual audit and quarterly review processes.
- Leadership over financial reporting processes and development/monitoring of internal controls over financial reporting.
- Support for audit readiness, including working with external auditors and completing audit requests.
- Financial modeling, budgeting, forecasting, liquidity planning, treasury oversight, and management/board reporting package preparation.
- Capital-markets and investor-reporting support, including financial materials, due diligence, and strategic finance analyses.
- Independence and Conflicts of Interest: The consultant is permitted to engage in other business activities, provided these do not create a conflict of interest or involve misuse of MIRA’s confidential information. Any actual conflicts must be promptly disclosed and addressed.
- Management Responsibility: The consultant’s services are advisory and supportive. Ultimate responsibility for business operations, disclosures, and financial filings remains with MIRA’s management and Board.
- Indemnification: MIRA Pharmaceuticals will indemnify the consultant to the fullest extent permitted by law and the company’s charter/bylaws. The company’s Insider Trading Policy applies to the consultant, including all restrictions on trading while in possession of material non-public information.
- Exclusivity of Services: The agreement covers only the fractional CFO services described. Any other consulting or operational services must be separately documented via written amendment.
Shareholder-Relevant & Potentially Price-Sensitive Information
- Strengthening Financial Leadership: The appointment of a dedicated fractional CFO, even as an external consultant, signals MIRA’s intent to professionalize and enhance its financial oversight and reporting. This is particularly relevant as the company seeks to meet evolving regulatory, audit, and investor expectations.
- Capital Markets Readiness: The explicit focus on capital-raising support, financial modeling, and investor communications may indicate that MIRA is preparing for future financing activities, partnerships, or other capital markets transactions. This could be a strategic move to position the company for growth or expansion, which is of direct interest to investors.
- Audit and Compliance Focus: Enhanced audit readiness and internal control measures may reduce operational risk, improve transparency, and increase investor confidence in MIRA’s financial statements.
- Insider Trading Compliance: The consultant is bound by insider trading restrictions, underscoring the company’s commitment to regulatory compliance and the protection of material non-public information.
Additional Details
- The consulting agreement does not constitute an employment relationship; the consultant remains an independent contractor.
- The consultant will allocate sufficient time and professional attention to meet the company’s needs, but is not required to devote full time exclusively to MIRA Pharmaceuticals.
- The agreement includes provisions for conflict of interest, confidentiality, and the proper handling of company information.
- There is an indemnification and advancement clause, as well as coverage under the company’s director and officer (D&O) insurance, for the consultant in connection with their services.
Conclusion
This announcement represents a material step for MIRA Pharmaceuticals as it seeks to strengthen its internal financial controls, reporting, and capital markets engagement. The engagement of a specialized fractional CFO may enhance the company’s credibility with investors, regulators, and potential partners. Shareholders should monitor further disclosures for any developments regarding financing, strategic partnerships, or operational milestones that may arise from this enhanced financial leadership.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult with their financial advisor and review official company filings before making investment decisions. The information herein is based solely on the company’s public filings and may be subject to change or updates.
